November 16th, 2026Diabetes Dialogue: Tubeless Mobi Clearance, CGM Choice, and Eversense FreedomDiana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.Read more
November 16th, 2026Diabetes Dialogue: OPTIMAL-DIABETES, Survodutide, and Orforglipron at AHA 2026Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.Read more
November 12th, 2026Diabetes Dialogue: Retatrutide Tops Semaglutide on A1C, Weight in T2DTRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.Read more
November 12th, 2026Diabetes Dialogue: CONNECT Trial Backs CGM in Non-Insulin Type 2 DiabetesTom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.Read more
November 9th, 2026The HCPFive: Top News for Healthcare Providers from the Week of 11/1Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.Read more
November 20th, 2026Monthly PVX108 Raises Peanut Tolerance in Children, With Brian Vickery, MDChildren receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.Read more
November 19th, 2026ABCs in Dermatology: Evolving Therapies and Dermatology's Role in Cutaneous Lupus CareAckerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.Read more
November 19th, 2026Q&A: Interpreting Pediatric Nemolizumab Data for AD, With Lawrence Eichenfield, MDLawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.Read more